T. Rowe Price Associates’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2015
Q2 | – | Sell |
-1,037,935
| Closed | -$101M | – | 2591 |
|
|
2015
Q1 | $101M | Buy |
1,037,935
+547,235
| +112% | +$53.4M | 0.02% | 607 |
|
|
2014
Q4 | $45.5M | Buy |
490,700
+484,100
| +7,335% | +$44.9M | 0.01% | 873 |
|
|
2014
Q3 | $454K | Buy |
6,600
+1,000
| +18% | +$68.8K | ﹤0.01% | 1980 |
|
|
2014
Q2 | $587K | Buy |
5,600
+900
| +19% | +$94.3K | ﹤0.01% | 1880 |
|
|
2014
Q1 | $390K | Hold |
4,700
| – | – | ﹤0.01% | 2023 |
|
|
2013
Q4 | $304K | Buy |
+4,700
| New | +$304K | ﹤0.01% | 2136 |
|